Investor Relations

Juno Therapeutics is building a fully integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors. Several product candidates have shown compelling clinical responses in clinical trials in refractory leukemia and lymphoma conducted to date. Juno's long-term aim is to leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases.

Download DocumentationJuno Corporate Presentation - May 2017

Recent News

DateTitle 
May. 23, 2017Juno Therapeutics Appoints Jay Flatley to Board of DirectorsPrinter Friendly Version
May. 17, 2017Juno Therapeutics to Present Key Clinical Data Updates on JCAR017 and JCAR014 at the 2017 American Society of Clinical Oncology Annual MeetingPrinter Friendly Version
May. 09, 2017Juno Therapeutics to Present at the Bank of America Merrill Lynch 2017 Health Care ConferencePrinter Friendly Version
May. 04, 2017Juno Therapeutics Reports First Quarter 2017 Financial ResultsPrinter Friendly Version

Upcoming Events

DateTitle
Jun. 05, 2017
Juno Therapeutics at the 2017 American Society of Clinical Oncology Annual Meeting

Past Events

DateTitle
05/16/17 3:40 p.m. PT
Juno Therapeutics at Bank of America Merrill Lynch 2017 Health Care Conference
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources